GSK plc (GSK) Form 6-K — Oct 13, 2026

GSK plc filed a Form 6-K on October 13, 2026 containing regulatory transaction notifications for its persons discharging managerial responsibilities and their closely associated persons. The filings cover automatic acquisitions of GSK ordinary shares and ADSs on October 8-9, 2026, resulting solely from dividend reinvestment, at £17.5904 per ordinary share on the London Stock Exchange and $46.5883 per ADS on the NYSE. Notified executives include CEO Luke Miels, Chief Scientific Officer Tony Wood, General Counsel James Ford, and multiple presidents and non-executive directors.

AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.